A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown Primary
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms CUPem
- 28 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 7 Jan 2019 to 28 Feb 2019.
- 30 Nov 2018 New trial record